
Dr. Ben Bikman discusses retatrutide, a next-generation metabolic drug that activates multiple receptors to aid in appetite suppression and energy expenditure.
📢 Ask Dr. Bikman’s Digital Mind (multilingual): https://benbikman.com/ben-bikmans-digital-ai-mind 📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com Topic: Retatrutide activates GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure and powerful liver fat reduction. Dr. Bikman argues that its best use is not as a permanent shortcut, but as a tool to help people regain control over food habits and eventually reduce reliance on medication. Summary: Dr. Ben Bikman explains retatrutide, a next-generation metabolic drug that activates three receptors at once: GLP-1, GIP, and glucagon. While semaglutide targets GLP-1 and tirzepatide targets GLP-1 plus GIP, retatrutide adds a third arm through glucagon receptor activation. This makes it distinct because GLP-1 and GIP mainly reduce food intake, while glucagon adds an energy-output effect by increasing fat oxidation, liver fat clearance, and energy expenditure. Dr. Bikman focuses especially on glucagon because it is the novel feature of retatrutide. In the liver, glucagon stimulates fat burning, suppresses new fat production, promotes hepatic fat clearance, and increases…
Host: Dr. Ben Bikman
Organizations: Insulin IQ
Products: Retatrutide, GLP-1, semaglutide, tirzepatide
Explore listener stats, chart rankings, contacts and more on the The Metabolic Classroom with Dr. Ben Bikman podcast page.